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Purpose
Few studies investigated roles of body mass index (BMI) on gastric cancer (GC) risk accord-
ing to Helicobacter pylori infection status. This study was conducted to evaluate associations
between BMI and GC risk with consideration of H. pylori infection information.
Materials and Methods
We performed a case-cohort study (n=2,458) that consists of a subcohort (n=2,193 inclu-
ding 67 GC incident cases) randomly selected from the Korean Multicenter Cancer Cohort
(KMCC) and 265 incident GC cases outside of the subcohort. H. pylori infection was 
assessed using an immunoblot assay. GC risk according to BMI was evaluated by calculating
hazard ratios (HRs) and their 95% confidence intervals (95% CIs) using weighted Cox hazard
regression model. 
Results
Increased GC risk in lower BMI group (< 23 kg/m2) with marginal significance (HR, 1.32;
95% CI, 0.98 to 1.77) compared to the reference group (BMI of 23-24.9 kg/m2) was 
observed. In the H. pylori non-infection, both lower (< 23 kg/m2) and higher BMI (! 25 kg/m2)
showed non-significantly increased GC risk (HR, 10.82; 95% CI, 1.25 to 93.60 and HR,
11.33; 95% CI, 1.13 to 113.66, respectively). However, these U-shaped associations 
between BMI and GC risk were not observed in the group who had ever been infected by 
H. pylori.  
Conclusion
This study suggests the U-shaped associations between BMI and GC risk, especially in sub-
jects who had never been infected by H. pylori.
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Introduction
Globally, gastric cancer (GC) holds the fourth and fifth
rank of cancer incidence in males and females, respectively
and is the third leading cause of cancer death in both sexes
worldwide [1]. With the combination of high incidence and
poor survival, GC is one of main contributor to the cancer
burdens worldwide [2]. Korea is one of the countries show-
ing highest GC incidence rate (age-standardized rate [ASR],
35.8 per 100,000 persons in 2014) and mortality rate (ASR, 9.7
per 100,000 persons in 2014) in the world [3]; therefore, ver-
ifying etiologic factors of GC is a great concern. 
In recent decades, increase in obesity is a noticeable epi-
demiologic phenomenon in worldwide [4] and obesity has
been considered as an attributable factor of several types of
cancer incidence, such as colorectal, breast, endometrial, kid-
ney, esophageal, and gastric cardia cancers [5]. Based on 
elevated gastric cardia cancer incidence coinciding with the
increase in obesity, a number of studies conducted in West-
ern populations showed positive association between high
body mass index (BMI) and gastric cardia cancer incidence
[6-8]. In a recent meta-analysis, summary relative risk (SRR)
of gastric cardia caner in obese group (BMI ! 30 kg/m2) was
reported as 1.82 (95% confidence interval [CI], 1.32 to 2.49)
compared to normal weight group (BMI of 18.5-24.9 kg/m2).
However, evidence on association between obesity and gas-
tric non-cardia cancer (SRR, 1.00; 95% CI, 0.87 to 1.15) was
not found in the same study [9]. Controversially, recent large
scaled cohort studies reported elevated GC risk in low BMI
group (BMI < 22 kg/m2) [10] and significantly decreased risk
of gastric non-cardia cancer in population with high BMI 
(! 23 kg/m2) than low BMI group (< 20.32 kg/m2) [11] , hence
further verification of relationship between BMI and GC is
still needed.
The proportion of gastric cardia cancer is higher in the
Western population than amongst Asians [12,13]. Contrary
to the Western population, gastric non-cardia cancer com-
prises a larger proportion in the East Asian populations, and
particularly in the Korean population, gastric non-cardia can-
cers are responsible for over 95% of total GC [14]. 
Moreover, the prevalence of Helicobacter pylori infection, a
group I carcinogen defined by the International Agency for
Research on Cancer (IARC) [15], is higher in Asian countries
compared to Western countries. The East Asian strains of H.
pylori were also reported to be more virulent to gastric car-
cinogenesis than the Western strains of H. pylori [16]. Several
studies reported the inverse association between H. pylori
infection prevalence and BMI level [17]. These results infer
that underweight population probably have high risk of gas-
tric non-cardia cancer due to high prevalence of H. pylori
infection. However, previous studies did not in fact measure
H. pylori infection status as a potential confounder on the 
association between gastric non-cardia cancer risk and BMI;
thus the association between BMI and gastric non-cardia can-
cer according to H. pylori infection is not well-characterized. 
Based on the differences in gastric non-cardia cancer inci-
dence rates, prevalence of H. pylori infection and its strains,
and the proportions of the population with extremes of BMI
between the Asian countries and Western countries, we reali-
zed the necessity to focus on the association between low
BMI and GC risk in Asia. Hence, we carried out a study (1)
to assess GC risk according to BMI while controlling the 
potential confounding effect of H. pylori infection, (2) to 
investigate the potential effect modification by H. pylori
infection on the association between BMI and GC risk, (3) to
evaluate potential difference in association between H. pylori
and GC risk according to BMI level in the case-cohort study
which is based on the Korean Multicenter Cancer cohort
(KMCC).
Materials and Methods
1. Data and study subjects
This study was designed within the population-based
prospective KMCC which is constructed to assess risk factors
related to cancer incidence and mortality in Korea. The
KMCC participants were recruited from the four urban and
rural areas (Haman, Chungju, Uljin, and Pohang) between
1993 and 2004. All participants signed an informed consent
form [18]. 
This study was conducted in two observational study 
designs, a prospective cohort study and a case-cohort study.
We tried to assess H. pylori infection status in order to adjust
potential confounding effect of H. pylori. Because entire 
cohort was too large to test H. pylori infection status of all
subjects, we choose case-cohort study design which is effi-
cient in the aspect of reducing time and cost by selecting sub-
set of entire cohort subjects. 
Flowchart of subject selection on total cohort and case-
cohort study is shown in the S1 Fig. After excluding the sub-
jects without information on height or weight measures,
19,016 subjects were defined as the total cohort study popu-
lation and 485 incident GC cases were identified in the total
cohort study subjects. Plasma samples for assessing H. pylori
infection status had been collected from 9,402 subjects includ-
ing 332 incident GC cases among 19,016 total cohort subjects.
We stratified these 9,402 subjects with plasma sample accord-
ing to sex and age (10-year interval). Then, we randomly
sampled 24% of subjects in each strata to constitute the sub-
cohort by reflecting sex and age structure of the KMCC. After
excluding subjects with insufficient or poor condition of
plasma sample, a total of 2,200 subjects (about 23%) were 
defined as eligible subjects for subcohort in this study. Num-
ber of GC incident cases within the subcohort and outside of
the subcohort were 67 and 265 cases, respectively. 
We assessed H. pylori infection status and IgG seropositiv-
ity to H. pylori virulence factors of eligible subjects for sub-
cohort (n=2,200) and GC incidence cases outside of the sub-
cohort (n=265). There were seven subjects whose H. pylori
infection status or IgG antibody to virulence factors were not
measured due to insufficient sample volume or inadequate
sample condition. Hence, a total of 2,193 subjects were 
defined as the subcohort population after excluding subjects
whose H. pylori infection status or IgG antibody to virulence
factors were not measured. Finally, a total number of 2,458
case-cohort subjects were denoted by integrating the subco-
hort subjects (n=2,193) and GC incident cases outside of the
subcohort (n=265). 
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2. Outcome assessment 
Incident GC cases in the KMCC were ascertained through
the record linkage between the KMCC data and the national
cancer registry data. Death certificate only cases were also
confirmed through linking the national death certificate of
the National Statistical Office to the KMCC data. A total of
508 incident GC cases among the total KMCC participants
were identified until December 31, 2013. After excluding GC
cases without information on height or weight, 485 GC cases
were left in the total cohort study. We measured H. pylori
infection status of case-cohort study subjects. Because we
could not assess H. pylori infection status of 153 GC cases due
to insufficient volume or unstable condition of plasma sam-
ples, a total of 332 GC cases with information of H. pylori
infection status were included in the case-cohort study.
3. Exposure assessment: BMI 
Information on individual characteristics such as demo-
graphic factors, lifestyle factors, and past medical history was
collected using a standardized interview-based question-
naire. Anthropometric indices such as height, weight, waist
and hip circumferences were also measured by the study
team. Height, the perpendicular distance between the top of
head and the heel after taking off shoes and standing with
their back against the wall straightly, and weight of study
subjects were measured by skilled investigators on the same
day of questionnaire interview at the cohort enrollment.
Measurements of height and weight were conducted twice
and the mean value was used in this study. 
BMI (kg/m2) was computed in accordance with its defini-
tion: weight (kg) divided by square of the height (m2). Because
World Health Organization (WHO) BMI classification was
proposed to reflect risk for mortality and non-communicable
diseases related to death, such as type 2 diabetes and cardio-
vascular disease [19], other BMI criteria might be more infor-
mative to indicate GC risk. Recent cohort studies also repor-
ted significant change in GC risk in group with BMI around
of 23.0 kg/m2, hence we applied modified criterion of BMI
in several ways as follows:
(a) < 18.5, 18.5-22.9, 23-24.9 (reference), 25-29.9, and 
! 30 kg/m2
(b) < 23, 23-24.9 (reference), and ! 25 kg/m2
(c) < 18.5, 18.5-22.4, 22.5-24.9 (reference), 25-27.4, and 
! 27.5 kg/m2
(d) < 22.5, 22.5-24.9 (reference), and ! 25 kg/m2
(e) < 23 kg/m2 and ! 23 kg/m2 (reference)
When we apply BMI category (a) to analysis, too small
number of GC cases were included in one category. Thus, we
made BMI category (b) by combining each of two lower and
two higher BMI groups than reference group as one group.
Because small number of GC cases were included in the ref-
erence group of BMI category (a) and (b) in the case-cohort
study, we conducted sensitivity analysis by slightly changing
criteria of BMI category (a) as BMI category (c). BMI category
(d) was also determined by combining each of two lower and
two higher BMI groups in category (c) as one BMI group.
4. Exposure assessment: Measurement of H. pylori infec-
tion status 
Specimens including serum, plasma, buffy coat, packed
red blood cell, and spot urine were also collected from the
KMCC participants and stored in standardized stable condi-
tion (–70" for blood samples and –20°C for spot urine sam-
ples) [18]. Cytotoxin-associated gene A (CagA) and vacuo-
lating cytotoxin A (VacA) has been known for virulence fac-
tors of H. pylori. CagA and VacA have been reported that
these virulence factors are associated with cellular responses
related to carcinogenesis such as excessive cell proliferation,
inhibition of apoptosis, and excessive inflammatory respon-
ses [20]. Hence, we assessed seropositivity of CagA and
VacA IgG along with H. pylori infection status. 
Because plasma sample collected at cohort enrollment
were the sole specimen to assess H. pylori infection status and
the invasive endoscopy (a gold standard of H. pylori test) and
a noninvasive reliable Urea Breath test was not easy to apply
in the setting of the community population group, we used
immunoblot assay, the Helico Bolt 2.1TM (MP Biomedicals
Asia Pacific, Singapore), to test H. pylori infection and
seropositivity on CagA and VacA IgG. The validity of Helico
Blot 2.1 was fairly good for sensitivity, 99%; for specificity,
98% [21]. 
Procedure for immunoblot assay is as follows: nitrocellu-
lose strips were diluted with 2 mL of diluted wash buffer and
were incubated for 5 minutes at room temperature on a rock-
ing platform. The plasma samples were collected at baseline
survey and frozen at –70°C until analysis; 2 mL of blotting
buffer was added to each well containing 2 µL of plasma or
positive/negative controls. After incubating for 1 hour at
room temperature on a rocking platform, the plates were
washed three times with 2 mL of diluted wash buffer allow-
ing 5 minutes soak on the rocking platform between each
wash. Two milliliters of working conjugate solution was
added to the wells and was incubated for 1 hour at room
temperature. After aspirating the conjugate and washing
three times, 2 mL of substrate solutions was added. Plates
were shaken at room temperature for 15 minutes and washed
three times, the same as above. Each strip was interpreted
according to the recommended criteria in manufacturer’s 
instruction.
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5. Statistical analysis
Basic characteristics between group with BMI < 23 kg/m2
and group with BMI ! 23 kg/m2 were compared by conduct-
ing the Pearson’s chi-square test for categorical variables and
Student t test for numerical variables in both total cohort and
case-cohort study.
Differences in the mean of age, height, weight, and cohort
follow-up time (year) along with frequency of sex, GC cases,
education years (< 12 years vs. ! 12 years), ever smoking,
more or equal to 400 cigarettes (yes vs. no), alcohol drinking
(ever vs. never drinker), history of gastritis, H. pylori ever 
infection (yes vs. no), CagA-secreting H. pylori infection (pos-
itive vs. negative) between the low and high BMI groups
were considered.
Hazard ratios (HRs) and their 95% CIs of GC incidence 
according to BMI level in the total cohort population were
calculated by using the Cox proportional hazards regression
models. We included age, sex, and year at cohort enrollment
in the Cox hazard regression model and variables showing
statistically significant differences between low and high
BMI groups (education, cigarette smoking, and alcohol drin-
king) were also considered for adjustment in the total cohort
study. 
In case of the case-cohort study, GC risks according to BMI
level or H. pylori infection were computed using the weighted
Cox proportional hazard model. H. pylori infection status was
additionally adjusted in the weighted Cox proportional haz-
ard regression model when GC risk according to BMI level
was evaluated. We used the Barlow’s weighting method in
the case-cohort study [22]. Weight of all GC cases in the case-
cohort study were assigned as 1 and weight of controls were
assigned as inverse of sample fraction defined as the propor-
tion of subcohort controls within the total cohort controls.
We also conducted stratified analysis by H. pylori infection
status to assess effect modification by H. pylori on the associ-
ation between BMI and GC risk. Subgroup of individuals
with H. pylori infection was further considered according to
CagA and VacA virulence factors (group with CagA-secret-
ing H. pylori infection, CagA+; group with both CagA-secret-
ing H. pylori and VacA-secreting H. pylori infection, CagA+
VacA+).
We also assessed differences in GC risk according to H. 
pylori infection among BMI categories (< 23 kg/m2, 23-24.9
kg/m2, and ! 25 kg/m2) to investigate effect modification by
BMI on the association between H. pylori and GC risk. 
Sensitivity analyses for cardia and non-cardia GC devel-
opment were performed. Non-cardia GC category included
GC cases with unspecified locations and missing T-code
since non-cardia GC consisted of more than 95% of total GC
cases in Korean population [14]. 
All statistical analysis was two-sided with alpha error of
5% and were performed using SAS software ver. 9.4 (SAS 
Institute Inc., Cary, NC).
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Total cohort (n=19,016) Case-cohort (n=2,458)
Characteristic Low BMIa) High BMIa) p-value Low BMI
a) High BMIa) p-value(n=8,645) (n=10,371) (n=1,168) (n=1,290)
Age (yr) 53.6±16.5 53.8±12.4 0.28 56.8±14.7 54.1±12.1 < 0.01
Height (cm) 158.0±8.9 157.1±8.8 < 0.01 158.9±9.0 157.8±8.9 < 0.01
Weight (kg) 52.0±7.1 64.1±8.7 < 0.01 52.6±7.2 64.5±8.8 < 0.01
Follow-up (yr) 12.9 (9.9-16.5) 12.4 (9.9-16.4) 0.93 12.9 (7.4-15.4) 13.2 (10.4-17.3) < 0.01
Male 3,905 (45.2) 3,714 (35.8) < 0.01 650 (55.7) 554 (43.0) < 0.01
GC cases 277 (3.2) 208 (2.0) < 0.01 193 (16.5) 138 (10.8) < 0.01
Education ! 12 yr 1,122 (13.1) 1,456 (14.2) 0.04 139 (11.9) 190 (14.8) 0.04
Ever smokersb) 3,670 (43.1) 3,244 (31.7) < 0.01 594 (51.1) 470 (36.8) < 0.01
Ever alcohol drinkers 3,759 (44.4) 4,124 (40.4) < 0.01 568 (48.7) 550 (43.0) < 0.01
History of gastritis 1,600 (21.7) 1,788 (20.1) 0.78 160 (21.3) 152 (19.2) 0.31
Helicobacter pylori–infected - - 996 (85.3) 1,108 (85.9) 0.66
CagA+H. pylori-infected - - 952 (81.5) 1,061 (82.3) 0.63
Table 1. General characteristics of cohort and case-cohort study subjects within the Korean Multicenter Cancer Cohort
(KMCC), 1993-2004
Values are presented as mean±standard deviation, median (IQR) for continuous variables and number (%) for category vari-
ables. GC, gastric cancer; CagA, cytotoxin-associated gene A. a)Low BMI indicates < 23.0 kg/m2; high BMI indicates ! 23.0
kg/m2, b)Ever smoking is defined as past and current smoking more or equal to 400 cigarettes.
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6. Ethical statement 
This study protocol was approved by the institutional 
review boards of Seoul National University Hospital (H-01-
10-084-002 and H-1310-082-528) and performed in accor-
dance with the principles of the Declaration of Helsinki.
Written informed consents were obtained.
Results
1. Characteristics of study subjects
The general characteristics were presented in Table 1. Sub-
jects in the high BMI group were more likely to be women,
have a high level of education compared to subjects in the
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GC development Non-cardia GC developmentb)
BMI (kg/m2) Person- No. HR (95% CI)a) Person- No. HR (95% CI)a)year year
Total cohort (n=19,016)
< 18.5 10,903 29 1.36 (0.89-2.08) 10,903 29 1.41 (0.92-2.17)
18.5-22.9 100,613 248 1.38 (1.08-1.76) 100,559 239 1.38 (1.08-1.77)
23.0-24.9 57,776 90 1.00 ( 57,758 87 1.00 (
25.0-29.9 67,418 107 1.13 (0.85-1.50) 67,395 105 1.15 (0.86-1.53)
! 30.0 8,515 11 1.18 (0.63-2.20) 8,515 11 1.21 (0.64-2.27)
< 18.5 10,903 29 1.36 (0.89-2.08) 10,903 29 1.41 (0.92-2.17)
18.5-22.9 100,613 248 1.38 (1.08-1.76) 100,559 239 1.38 (1.08-1.77)
23.0-24.9 57,776 90 1.00 ( 57,758 87 1.00 (
25.0-27.4 48,060 76 1.11 (0.82-1.51) 48,038 74 1.12 (0.82-1.53)
! 27.5 27,873 42 1.18 (0.81-1.70) 27,873 42 1.21 (0.84-1.75)
< 23.0 111,516 277 1.38 (1.08-1.75) 111,462 268 1.38 (1.08-1.77)
23.0-24.9 57,776 90 1.00 ( 57,758 87 1.00 (
! 25.0 75,933 118 1.14 (0.86-1.50) 75,910 116 1.15 (0.87-1.52)
Case-cohort (n=2,458)
< 18.5 1,156 23 1.22 (0.74-2.01) 1,156 23 1.28 (0.77-2.12)
18.5-22.9 12,259 170 1.33 (0.99-1.79) 12,227 163 1.32 (0.98-1.79)
23.0-24.9 7,208 62 1.00 ( 7,204 60 1.00 (
25.0-29.9 8,547 71 1.08 (0.77-1.52) 8,524 69 1.08 (0.76-1.53)
! 30.0 903 6 1.01 (0.43-2.36) 903 6 1.02 (0.44-2.39)
< 18.5 1,156 23 1.22 (0.74-2.01) 1,156 23 1.28 (0.77-2.12)
18.5-22.9 12,259 170 1.33 (0.99-1.79) 12,227 163 1.32 (0.98-1.79)
23.0-24.9 7,208 62 1.00 ( 7,204 60 1.00 (
25.0-27.4 6,094 51 1.11 (0.76-1.61) 6,071 49 1.10 (0.75-1.61)
! 27.5 3,356 26 1.01 (0.63-1.61) 3,356 26 1.03 (0.65-1.65)
< 23.0 13,415 193 1.32 (0.98-1.77) 13,383 186 1.32 (0.98-1.78)
23.0-24.9 7,208 62 1.00 ( 7,204 60 1.00 (
! 25.0 9,450 77 1.07 (0.77-1.51) 9,427 75 1.08 (0.76-1.52)
Table 2. Association between BMI and GC risk in the total cohort and case-cohort study within the KMCC, 1993-2004
BMI, body mass index; GC, gastric cancer; KMCC, Korean Multicenter Cancer Cohort; HR, hazard ratio; CI, confidence 
interval. a)Adjusted for age, sex, year of recruitment, education years (< 12 years vs. ! 12 years), ever smoking more or equal
to 400 cigarettes (yes vs. no), and alcohol drinking status (yes vs. no), b)Non-cardia GC including unspecified cases (9% of
total GC cases). The results for cardia GC development were not presented due to non-estimation of parameter estimators
and their 95% CIs by sparse cardia GC cases (n=14).
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low BMI group. A relatively low proportion of ever smokers
and ever drinkers were found in the high BMI group com-
pared to the low BMI group. In general, we also confirmed
the consistent results in both total cohort and case-cohort
population. Additional difference of age in the total cohort
and difference of follow-up period in the case-cohort study
were found. 
2. GC risk according to BMI level in the total cohort study 
GC risk according to BMI categories in the total cohort is
presented in Table 2. There was an increased GC risk in
groups with BMI < 18.5 kg/m2 or of 18.5-22.9 kg/m2 com-
pared to the reference group (BMI of 23-24.9 kg/m2) in the
total cohort study (HR, 1.36; 95% CI, 0.89 to 2.08 for group
with BMI < 18.5 kg/m2 and HR, 1.38; 95% CI, 1.08 to 1.76 for
group with BMI of 18.5-22.9 kg/m2, respectively; however,
it was non-significant in group with BMI < 18.5 kg/m2.
In contrast, there was no statistically significant associa-
tions between BMI ! 25 kg/m2 and GC risk (HR, 1.13; 95%
CI, 0.85 to 1.50 for group with BMI 25-29.9 kg/m2 and HR,
1.18; 95% CI, 0.63 to 2.20 for group with BMI ! 25 kg/m2, res-
pectively). 
3. GC risk according to BMI level in the case-cohort study 
We also assessed GC risk according to BMI with additional
adjustment of H. pylori infection in the case-cohort study
(Table 2). Similar results to the total cohort study on the 
association between BMI and GC risk were observed in the
case-cohort study. Compared to the reference group (BMI of
23-24.9 kg/m2), group with BMI of < 18.5 kg/m2 or 18.5-22.9
kg/m2 were associated with increased GC risk (HR, 1.22; 95%
CI, 0.74 to 2.01 for group with BMI < 18.5 kg/m2 and HR,
1.33; 95% CI, 0.99 to 1.79 for group with BMI of 18.5-22.9
kg/m2, respectively), although the associations were not sta-
tistically significant. 
4. Effect modification by H. pylori infection on associations
between BMI and GC risk in the case-cohort study
Further, we performed analysis on the association between
Cancer Res Treat. 2019;51(3):1107-1116
GC development Non-cardia GC developmenta)
BMI (kg/m2) Person- No. Stratification Person- No. Stratificationyear HR (95% CI)b) year HR (95% CI)b)
Never H. pylori infected
< 23.0 2,017 12 10.82 (1.25-93.60) 2,017 12 12.07 (1.34-108.39)
23.0-24.9 1,071 1 1.00 ( 1,071 1 1.00 (
! 25.0 1,358 7 11.33 (1.13-113.66) 1,345 6 9.95 (0.91-108.31)
Ever H. pylori infected 
< 23.0 11,398 181 1.26 (0.93-1.70) 11,366 174 1.26 (0.93-1.71)
23.0-24.9 6,137 61 1.00 ( 6,133 59 1.00 (
! 25.0 8,091 70 1.03 (0.71-1.40) 8,082 69 1.05 (0.72-1.44)
H. pylori+CagA+
< 23.0 10,886 174 1.26 (0.93-1.72) 10,855 167 1.26 (0.92-1.72)
23.0-24.9 5,895 59 1.00 ( 5,891 57 1.00 (
! 25.0 7,762 68 1.12 (0.72-1.65) 7,753 67 1.03 (0.72-1.48)
CagA+VacA+
< 23.0 8,494 126 1.46 (1.01-2.11) 8,468 120 1.44 (0.99-2.10)
23.0-24.9 4,866 41 1.00 ( 4,862 40 1.00 (
! 25.0 6,397 51 1.14 (0.75-1.72) 6,388 50 1.14 (0.75-1.74)
Table 3. Association with body mass index for GC risk by Helicobacter pylori infection in the case-cohort study within the
KMCC, 1993-2004
GC, gastric cancer; KMCC, Korean Multicenter Cancer Cohort; BMI, body mass index; CagA+, cytotoxin-associated gene A
(CagA)–secreting H. pylori infection; CagA+VacA+, both CagA-secreting H. pylori and vacuolating cytotoxin A (VacA)–
secreting H. pylori infection. a)Non-cardia GC including unspecified cases (9% of total GC cases). The results for cardia GC
development were not presented due to non-estimation of parameter estimators and their 95% CIs by sparse cardia GC cases
(n=14), b)Adjusted for age, sex, year of recruitment, education years (< 12 years vs. ! 12 years), ever smoking more or equal
to 400 cigarettes (yes vs. no), and alcohol drinking status (yes vs. no). 
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BMI and GC risk stratified by H. pylori infection status and
CagA-secreting H. pylori infection status (Table 3). BMI < 23
kg/m2 and ! 25 kg/m2 were associated with increased GC
risk (HR, 10.82; 95% CI, 1.25 to 93.60 for BMI < 23 kg/m2 and
HR, 11.33; 95% CI, 1.13 to 113.66 for BMI ! 25 kg/m2, respec-
tively) amongst subjects without H. pylori infection. In con-
trast, there were no statistically significant increase in GC risk
in the group with BMI < 23 kg/m2 and ! 25 kg/m2 who were
H. pylori positive (HR, 1.26; 95% CI, 0.93 to 1.70 for BMI < 23
kg/m2 and HR, 1.03; 95% CI, 0.71 to 1.40 for BMI ! 25 kg/m2, 
respectively).
Because only one GC cases were included in the reference
group, we conducted sensitivity analysis after changing ref-
erence group as subjects with BMI of 22.5-24.9 kg/m2
(S2 Table). Similar U-shaped association between BMI and
GC risk in subjects who were not infected by H. pylori was
found even when we changed reference group. No statisti-
cally significant differences in GC risk by BMI categories in
subjects positive for H. pylori infection were observed. 
5. Difference in association between H. pylori infection and
GC risk according to BMI level in the case-cohort study
GC risk according to H. pylori infection status in stratified
group by BMI level was also conducted (Table 4). In the
group with BMI < 23 kg/m2, H. pylori infection was associ-
ated with about 2-fold higher GC risk (HR, 2.04; 95% CI, 1.13
to 3.70). Elevated GC risk according to H. pylori infection was
also observed in group with BMI of 23-24.9 kg/m2 (HR,
10.52; 95% CI, 1.44 to 76.67). In contrary, there was no statis-
tically significant difference in GC risk by H. pylori infection
in group with BMI ! 25 kg/m2 (HR, 1.73; 95% CI, 0.78 to
3.82). Even when we used other BMI categories (< 22.5, 22.5-
24.9, and ! 25 kg/m2), similar patterns on the association 
between H. pylori infection status and GC risk were observed.
6. Sensitivity analysis by GC anatomical location
In cardia GC analysis, the risk estimates were not calcu-
lated due to sparse GC cases (only 14 cases in total subjects),
and thus the results were not shown in this paper. Only the
GC development Non-cardia GC developmenta)
Person- No. Stratification Person- No. Stratificationyear HR (95% CI)b) year HR (95% CI)b)
BMI < 23.0 kg/m2
Never infected 2,017 12 1.00 ( 2,017 12 1.00 (
Ever infected 11,398 181 2.04 (1.13-3.70) 11,366 174 1.99 (1.10-3.62)
H. pylori+CagA+ 10,886 174 2.06 (1.14-3.74) 10,855 167 2.01 (1.11-3.65)
CagA+VacA+ 8,494 126 2.03 (1.11-3.72) 8,468 120 1.97 (1.08-3.62)
BMI 23.0-24.9 kg/m2
Never infected 1,071 1 1.00 ( 1,071 1 1.00 (
Ever infected 6,137 61 10.52 (1.44-76.67) 6,133 59 9.98 (1.37-72.78)
H. pylori+CagA+ 5,895 59 10.38 (1.42-75.70) 5,891 57 9.84 (1.35-71.84)
CagA+VacA+ 4,866 41 12.17 (1.63-90.02) 4,862 40 11.59 (1.55-86.69)
BMI ! 25.0 kg/m2
Never infected 1,358 7 1.00 ( 1,345 6 1.00 (
Ever infected 8,091 70 1.73 (0.78-3.82) 8,082 69 2.02 (0.86-4.72)
H. pylori+CagA+ 7,762 68 1.80 (0.81-4.00) 7,753 67 2.11 (0.90-4.94)
CagA+VacA+ 6,397 51 1.73 (0.76-3.93) 6,388 50 2.03 (0.85-4.87)
Table 4. The association between Helicobacter pylori infection and GC risk by BMI level in the case-cohort study within the
KMCC, 1993-2004
GC, gastric cancer; BMI, body mass index; KMCC, Korean Multicenter Cancer Cohort; HR, hazard ratio; CI, confidence 
interval; CagA+, cytotoxin-associated gene A (CagA)–secreting H. pylori infection; CagA+VacA+, both CagA-secreting H.
pylori and vacuolating cytotoxin A (VacA)–secreting H. pylori infection. a)Non-cardia GC including unspecified cases (9% of
total GC cases). The results for cardia GC development were not presented due to non-estimation of parameter estimators
and their 95% CIs by sparse cardia GC cases (n=14), b)Adjusted for age, sex, year of recruitment, education years (< 12 years
vs. ! 12 years), ever smoking more or equal to 400 cigarettes (yes vs. no), and alcohol drinking status (yes vs. no).
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results for non-cardia GC development were additionally
presented in the Tables 2-4. As the result, the associations be-
tween BMI and GC risk in subgroup population without car-
dia GC cases, were persistent. 
Discussion
About 1.3-fold increased GC risk in population with low
BMI (< 23 kg/m2) was found in both total cohort and case-
cohort studies, but the association was marginally significant
in the case-cohort study. In the case-cohort study, BMI levels
showed U-shaped association with GC risk, especially in the
H. pylori non-infected group: the risk of GC was higher in
two different groups such as lower BMI group (< 23 kg/m2)
or higher BMI group (! 25 kg/m2) compared with the refer-
ence BMI group (23-24.9 kg/m2).
A recently published large-scale cohort study in UK repor-
ted a reverse-J-shaped association between BMI and GC for
the first time in Western studies [10]. This study including
5.24 million subjects and 3,337 incident GC cases reported an
increased risk of GC in those with low BMI (< 20 kg/m2) as
well as in obese subjects. Results from China cohort study
also reported that high BMI (! 23.31 kg/m2) compared to low
BMI (< 20.32 kg/m2) was associated with reduced gastric
non-cardia cancer risk rather than increased risk, implying
significantly more elevated GC risk in low BMI group [11]. 
Our findings were analogous with those results above in
terms of demonstrating increased GC risk in population with
low BMI. However, significant associations between BMI
and GC risk results were obtained only in H. pylori non-
infected persons in our study. This suggests that H. pylori
has a very strong effect on the development of GC, whereas
BMI can play a modest role in the development of GC, as
compared to H. pylori infection. 
The link with gastric non-cardia cancer risk in obese pop-
ulation has not been fully established, and the explanation
to support increased GC risk in populations with low BMI
has so far been limited. 
However, the increased risk of GC in obese people can be
explained by biological changes, such as an increase in chro-
nic inflammation and a decrease in immune response in
obese people [23,24], which lead to contributing the chroni-
cization of inflammatory conditions and consequently go to
gastric carcinogenesis. This can be induced into carcinogen-
esis regardless of H. pylori infection. The increased risk of GC
in people with low BMI can be explained by the following
mechanisms. Smokers are more likely to have low BMI and
those with low BMI are more likely to have multiple nutrient
deficiencies [25]. These conditions lead to reduction of natu-
ral immunity, and in particular, the decrease of micronutri-
ents such as vitamins A, C, and E can cause the limit of 
antioxidant activity, which can lead to an increase of inflam-
matory reaction due to oxidative stress [26,27]. 
Our results show that the U-shaped association of BMI
with GC risk in non-infected individuals is more evident
than in H. pylori infected individuals. The risk of GC in all 
H. pylori infected individuals has already risen even in the
reference group (people with BMI of 23-24.9 kg/m2) at the
baseline risk of GC, due to H. pylori infection itself, and thus,
the GC risk of the high-risk groups (those with BMI < 23 kg/
m2 or those with BMI ! 25 kg/m2) does not seem to rise much
compared to the reference group. Conversely, in the H. pylori
non-infected individuals, the effect of BMI itself on GC risk
appears to be clearly demonstrated because major carcino-
genic factor, H. pylori infection, are not involved. In other
words, the H. pylori infection, a big carcinogenic factor, may
obscure the risk of GC by BMI in infected individuals due to
“Umbrella effect” by infection, whereas the effect of BMI on
GC risk is clearly expressed in non-infected individuals 
because of no “Umbrella effect” by infection. This may be
due to the fact that the effect of BMI is too weak for the 
development of GC compared to the effect of H. pylori infec-
tion. 
This study has some limitations. First, the number of inci-
dent GC cases was relatively small, limiting the statistical
power in stratified analysis. Though we found U-shaped 
relationship between BMI and GC risk in subjects not 
infected by H. pylori, only one GC case was included in the
reference group. Therefore, point estimate of GC risk by BMI
in H. pylori non-infected group might be overestimated. Sec-
ond, total energy expenditure or nutritional status was not
considered, because of insufficient information on food con-
sumption. Third, BMI information was based on height and
weight measured at the time of enrollment, only, and infor-
mation of BMI change during follow-up time could not be
taken into account. Fourth, the results in the H. pylori IgG Ab
test is limited because if the IgG Ab test is positive, it does
not mean an active infection because it is seen as positive in
both past and current infections. Fifth, in this cohort, 4.1%
GC cancer cases were detected by death certificate only
(DCO) (=22 DCO/485 total GC cases). Of total 463 GC cases
after excluding DCO cases, GC cases with no T-Code were
26 (5.7%) and those with unspecified anatomical location
(C169) were 66 (16.3%). A prior paper presenting the classi-
fication cardia and non-cardia GC in hospital setting repor-
ted the unspecified GC cases were 25% (n=50/200 cases) [28].
The DCO occurs due to the gap between the coverage years
of cancer registration data and those of death certificate data.
This KMCC data was first linked to cancer registry, death
certificate, and health insurance data (with confirmation
using medical record survey) in 2001. We found that those
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who were identified as confirmed cancer cases in the second-
ary data in 2001 were not confirmed in recent data. The rea-
son is because each institution had limited the retention year
of data. The other reason of DCO is due to incompleteness
of secondary data, such as the year of the application of the
secondary data source. In estimating the cancer incidence
and mortality rates reported by the WHO Globocan, the com-
pleteness of the data is evaluated by the DCO (%) of each
country (http://gco.iarc.fr/). 
This study has several strengths. It was designed as a
prospective cohort study and a case-cohort study. Both stud-
ies are based on prospectively collected data, thus time sequ-
ence between exposure and outcome is considered in these
study designs, which minimizes reverse causation. Matching
between cases and controls was not carried out in the case-
cohort study design; thus, effects of age or sex on develop-
ment of disease could be studied on the incidence of disease
in the study population. Unlike most previous published
studies on the association between BMI and GC which were
conducted in Western population, this study was conducted
on an East Asian population. Therefore, this study was appro-
priate to assess the association between BMI and gastric non-
cardia cancer. H. pylori infection status, a potential confoun-
der, was also adjusted in the case-cohort study. 
In conclusion, this study suggests that BMI levels are 
associated with GC risk in a U-shaped fashion, especially in
population without H. pylori infection.  
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